arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

OCULAR THERAPEUTIX, INC

OCUL
$10.01 ▼ -0.51 (-4.85%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

OCULAR THERAPEUTIX, INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B
Dividend Yield
Revenue Growth 0.1%
Op. Margin None
ROIC -12.5%
FCF / Share $-0.31
Trailing P/E
Price / Book 4.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.47M
— +0.1%
Net Income Profit after all expenses
$-88.61M
↓ -38.3%
Operating Margin Operating profit as % of sales
-472.3%
↓ -59.5%
FCF / Share Free cash flow per share
$-0.31
↑ +4.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
19
Financial Health
21
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters